Sagimet Biosciences Inc. Series A Common Stock (SGMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a cash flow conversion efficiency ratio of -0.042x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.70 Million) by net assets ($256.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Sagimet Biosciences Inc. Series A Common worth for the company's overall valuation and market capitalisation.
Sagimet Biosciences Inc. Series A Common Stock - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Sagimet Biosciences Inc. Series A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sagimet Biosciences Inc. Series A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sagimet Biosciences Inc. Series A Common Stock ranked by their cash flow conversion efficiency. See debt repayment capacity of Sagimet Biosciences Inc. Series A Common to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gifore Agricultural Machinery Chain Co Ltd
SHE:300022
|
-0.017x |
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
0.033x |
|
Berry Genomics Co Ltd
SHE:000710
|
-0.001x |
|
Beijing Scitop Bio Tech Co Ltd
SHE:300858
|
0.025x |
|
Guangdong Piano Customized Furniture Co Ltd
SHE:002853
|
0.016x |
|
Zaptec AS
OL:ZAP
|
0.579x |
|
Selamat Sempurna Tbk
JK:SMSM
|
0.072x |
|
Zhejiang Yingfeng Technology Co Ltd
SHG:605055
|
N/A |
Annual Cash Flow Conversion Efficiency for Sagimet Biosciences Inc. Series A Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Sagimet Biosciences Inc. Series A Common Stock from 2019 to 2025. View current stock price of Sagimet Biosciences Inc. Series A Common for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $111.38 Million | $-45.65 Million | -0.410x | -50.48% |
| 2024-12-31 | $155.81 Million | $-42.44 Million | -0.272x | -4.36% |
| 2023-12-31 | $91.06 Million | $-23.77 Million | -0.261x | -299.22% |
| 2022-12-31 | $-186.95 Million | $-24.49 Million | 0.131x | -4.51% |
| 2021-12-31 | $-158.26 Million | $-21.71 Million | 0.137x | +79.00% |
| 2020-12-31 | $-135.91 Million | $-10.42 Million | 0.077x | -8.98% |
| 2019-12-31 | $-125.31 Million | $-10.55 Million | 0.084x | -- |
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfun… Read more